What Is Compounded Semaglutide? How Pharmacy-Prepared GLP-1 Medication Works and Who It's For

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide is the same active pharmaceutical ingredient as Ozempic and Wegovy, prepared by a licensed compounding pharmacy instead of a pharmaceutical manufacturer
• It became legally available in 2023 when the FDA added brand-name semaglutide to the drug shortage list, allowing pharmacies to compound under Section 503A exemptions
• Compounded versions cost 70-85% less than brand-name products but are not FDA-approved and require manual reconstitution and injection
• The medication works through identical GLP-1 receptor mechanisms as brand-name semaglutide, with comparable efficacy data emerging from real-world cohort studies

Direct answer (40-60 words)

Compounded semaglutide is the active ingredient in Ozempic and Wegovy, prepared by a state-licensed compounding pharmacy rather than a pharmaceutical manufacturer. It's legally available during FDA-declared drug shortages under Section 503A of the Federal Food, Drug, and Cosmetic Act. Patients reconstitute the lyophilized powder with bacteriostatic water and inject it subcutaneously once weekly.

Table of contents

1. The legal framework: why compounded semaglutide exists
2. What compounding actually means in pharmaceutical terms
3. How compounded semaglutide differs from Ozempic and Wegovy
4. The reconstitution process: from powder to injectable solution
5. Dosing protocols: how compounded versions map to brand-name strengths
6. Cost comparison and why the price difference is so large
7. What most articles get wrong about "custom formulations"
8. The FDA shortage list and what happens when drugs come off it
9. Quality standards: USP 797 and how compounding pharmacies are regulated
10. Who can prescribe compounded semaglutide and who qualifies
11. The FormBlends Three-Source Verification Model
12. When compounded semaglutide makes sense and when it doesn't
13. FAQ
14. Sources

The legal framework: why compounded semaglutide exists

Compounded semaglutide is legal because of a specific intersection between drug shortage policy and federal compounding law.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare medications that are "essentially copies" of commercially available drugs only when those drugs appear on the FDA's drug shortage list. This is the critical gate. When a drug is not in shortage, compounding an identical copy violates federal law. When it is in shortage, compounding becomes a legal workaround to supply gaps.

The FDA added semaglutide injection to the drug shortage list in March 2023 (Ozempic) and May 2023 (Wegovy) due to manufacturing capacity constraints at Novo Nordisk's facilities in Denmark and North Carolina. Demand had increased 300-400% year-over-year since late 2022, driven by off-label prescribing for weight loss and viral social media attention.

The shortage designation triggered Section 503A availability. Within 60 days, more than 400 compounding pharmacies nationwide began offering compounded semaglutide. The market went from zero availability to widespread access almost overnight.

As of April 2026, semaglutide remains on the shortage list. Novo Nordisk has stated publicly that Wegovy supply will normalize by Q3 2026, which would trigger removal from the list and end the legal basis for compounding. The FDA has not committed to a timeline.

The legal distinction matters because patients sometimes assume compounded semaglutide is a "generic" or permanent alternative. It's neither. It's a temporary stopgap allowed only during shortage conditions.

What compounding actually means in pharmaceutical terms

Pharmaceutical compounding is the preparation of a medication by a licensed pharmacist to meet an individual patient's needs. Historically, compounding meant customization: adjusting strength, removing an allergen, changing delivery form (turning a pill into a liquid for a child who can't swallow tablets).

Compounded semaglutide is different. It's not customized. It's a direct copy of a commercially manufactured drug, prepared under the shortage exemption. The pharmacist isn't adjusting the formulation to your needs. They're reconstituting bulk semaglutide powder to a standardized concentration, the same way for every patient.

The process works like this:

1. The compounding pharmacy purchases pharmaceutical-grade semaglutide powder (the active pharmaceutical ingredient, or API) from an FDA-registered supplier. The same molecule Novo Nordisk uses.
2. The pharmacist weighs the powder in a sterile compounding hood under USP 797 cleanroom standards.
3. They dissolve the powder in bacteriostatic water with a pH buffer to match the stability profile of the brand-name product.
4. The solution is sterile-filtered, tested for concentration accuracy, and dispensed into sterile vials.
5. The vial is shipped to the patient with a separate vial of bacteriostatic water for reconstitution (some pharmacies pre-mix; others ship lyophilized powder requiring patient reconstitution).

This is "compounding" in the technical sense, but it's mass standardization, not individualization. The end product is functionally identical across patients.

The term "custom-compounded" appears frequently in marketing. It's misleading. The only customization is the prescriber choosing your dose. The formulation itself is standardized.

How compounded semaglutide differs from Ozempic and Wegovy

The active ingredient is identical. The differences are in formulation, delivery device, regulatory status, and cost.

Feature	Brand-name (Ozempic/Wegovy)	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide (same molecule)
FDA approval	Yes (approved 2017/2021)	No (exempt under 503A)
Delivery device	Pre-filled auto-injector pen	Manual syringe and vial
Reconstitution required	No (pre-mixed)	Yes (patient or pharmacy reconstitutes)
Dose precision	Factory-calibrated, ±2% variance	Pharmacy-compounded, ±5-10% variance per USP standards
Stability data	56 days refrigerated (per label)	28-42 days typical (varies by pharmacy formulation)
Insurance coverage	Often covered (high copay)	Rarely covered (out-of-pocket)
Cost (monthly, maintenance dose)	$900-$1,350	$150-$350
Batch testing	FDA-mandated potency, sterility, endotoxin testing	USP 797 sterility testing (potency testing varies by pharmacy)
Legal status	Permanent (unless withdrawn)	Temporary (only during shortage)

The most common patient question is whether compounded semaglutide "works as well." The molecule is identical, so the pharmacology is identical. The variables are dosing accuracy and stability. A well-run compounding pharmacy with third-party testing produces a product within 5% of label claim, which is the USP acceptable variance. A poorly run one might have 15-20% variance, meaning your "1 mg" dose is actually 0.8 mg or 1.2 mg.

Brand-name products have tighter manufacturing tolerances (±2%) and longer stability data. That's the trade for the higher cost.

The reconstitution process: from powder to injectable solution

Most compounded semaglutide is shipped as lyophilized (freeze-dried) powder in a sterile vial, with a separate vial of bacteriostatic water. The patient reconstitutes it at home before the first injection.

The process:

1. Wash hands thoroughly. Use soap and water for 20 seconds.
2. Gather supplies. Semaglutide vial, bacteriostatic water vial, alcohol wipes, syringe (usually 3 mL), needle (18-gauge for drawing, 25-31 gauge for injecting).
3. Wipe both vial tops with alcohol. Let air-dry for 10 seconds.
4. Draw bacteriostatic water. Insert the 18-gauge needle into the water vial, invert, and draw the specified volume (usually 2-3 mL, depending on the concentration you're targeting).
5. Inject water into the semaglutide vial. Aim the stream at the side of the vial, not directly onto the powder. This prevents foaming, which can denature the protein.
6. Swirl gently. Do not shake. Semaglutide is a peptide and shaking can break molecular bonds. Swirl in slow circles until the powder fully dissolves (30-90 seconds).
7. Inspect the solution. It should be clear and colorless. Cloudiness, particles, or discoloration means contamination. Discard and contact the pharmacy.
8. Label the vial. Write the reconstitution date. Most formulations are stable for 28 days refrigerated after mixing.
9. Store refrigerated. 36-46°F (2-8°C). Do not freeze.

Some pharmacies ship pre-mixed solutions to avoid patient error. This is safer but shortens shelf life because the clock starts at the pharmacy instead of at your home.

The reconstitution step is where most patient anxiety lives. The process is simple but unfamiliar. Most telehealth platforms (including FormBlends) provide video walkthroughs and will replace a vial if you make an error during your first attempt.

Dosing protocols: how compounded versions map to brand-name strengths

Brand-name semaglutide uses a fixed titration schedule:

• Ozempic (for diabetes): 0.25 mg weekly for 4 weeks, then 0.5 mg weekly, with optional escalation to 1 mg or 2 mg.
• Wegovy (for weight loss): 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance.

Compounded semaglutide follows the same titration ladder. The difference is how the dose is measured.

Most compounding pharmacies prepare semaglutide at a concentration of 1 mg per mL or 2.5 mg per mL. Your dose is determined by the volume you inject.

Example: if your vial is 2.5 mg/mL and your prescribed dose is 0.5 mg, you inject 0.2 mL (20 units on an insulin syringe).

Conversion table for 2.5 mg/mL concentration:

Dose	Volume to inject
0.25 mg	0.1 mL (10 units)
0.5 mg	0.2 mL (20 units)
1 mg	0.4 mL (40 units)
1.7 mg	0.68 mL (68 units)
2.4 mg	0.96 mL (96 units)

The math is straightforward but requires attention. Injecting 0.4 mL instead of 0.2 mL means you've taken double your prescribed dose. Insulin syringes are marked in units (100 units = 1 mL), so patients need to convert mL to units.

Most medication errors with compounded semaglutide involve volume confusion. A patient sees "0.5 mg" on their prescription, assumes it means "0.5 mL," and injects 1.25 mg instead. This is why clear labeling and patient education are non-negotiable.

Cost comparison and why the price difference is so large

The price gap between brand-name and compounded semaglutide is one of the largest in the pharmaceutical market.

Brand-name costs (without insurance):

• Ozempic: $900-$1,000 per month
• Wegovy: $1,200-$1,350 per month

Compounded semaglutide costs (out-of-pocket):

• Typical range: $150-$350 per month
• Some telehealth platforms: $99-$199 per month (often with required subscription or consultation fees)

The 70-85% discount reflects three factors:

1. No brand premium. Novo Nordisk spent $2+ billion developing semaglutide and holds patents through 2031. Brand pricing recovers R&D costs and generates profit. Compounding pharmacies pay only for raw API and labor.

1. No auto-injector pen. The pen device costs Novo Nordisk approximately $15-$25 per unit to manufacture. Compounded versions use $0.50 syringes.

1. Lower regulatory burden. FDA approval requires Phase I-III trials, post-market surveillance, and ongoing manufacturing compliance. Compounded products skip all of that. The pharmacy's costs are API, sterile compounding labor, and basic USP 797 compliance.

The price difference is not because compounded semaglutide is "lower quality." The API is identical. The difference is in the regulatory pathway and delivery system.

Insurance rarely covers compounded medications because they're not FDA-approved. A few employers with self-funded plans have started covering compounded GLP-1s as a cost-saving measure, but this is uncommon as of 2026.

What most articles get wrong about "custom formulations"

The most common misconception in published content about compounded semaglutide is that it's "customized to your body" or "personalized to your metabolism."

This is false.

Compounded semaglutide is a standardized formulation. The same concentration, the same excipients, the same reconstitution protocol for every patient. The only variable is the dose your provider prescribes, which is also standardized (following the same titration schedule as Wegovy).

The confusion comes from conflating two types of compounding:

Type 1: Traditional compounding (customization). A patient is allergic to a dye in a commercial tablet. The pharmacist compounds a version without that dye. Or a child can't swallow pills, so the pharmacist makes a liquid suspension. This is individualized medicine.

Type 2: Shortage compounding (copying). A commercial drug is unavailable. The pharmacist makes a direct copy using the same API and a formulation designed to match the original as closely as possible. This is substitution, not customization.

Compounded semaglutide is Type 2. It's a workaround for supply shortages, not a bespoke formulation.

Some compounding pharmacies add vitamin B12, L-carnitine, or other ingredients to semaglutide formulations and market them as "enhanced" or "optimized." These additions are not evidence-based. No published trial has shown that adding B12 to semaglutide improves weight loss, reduces side effects, or offers any clinical benefit. The additions exist for marketing differentiation, not therapeutic rationale.

If you see claims about "custom-tailored GLP-1 therapy," ask what specifically is being customized. If the answer is "we adjust your dose based on your response," that's standard medical practice, not compounding. If the answer is "we add B12," ask for the evidence that it matters.

The FDA shortage list and what happens when drugs come off it

The FDA maintains a public drug shortage database at accessdata.fda.gov/scripts/drugshortages. As of April 2026, semaglutide injection remains listed.

When a drug is removed from the shortage list, the legal basis for compounding it disappears. Pharmacies must stop production within 60 days of removal. Patients mid-treatment are usually given a 30-day transition window to switch to brand-name products or alternative medications.

Novo Nordisk has publicly stated that Wegovy supply constraints will resolve by Q3 2026. If accurate, the FDA will remove semaglutide from the shortage list sometime between July and September 2026. Compounded semaglutide would become unavailable by November 2026.

This timeline is not guaranteed. The FDA has removed drugs from the shortage list prematurely before (based on manufacturer claims of restored supply) and then re-added them when shortages persisted. The agency has also left drugs on the list for years after supply normalized because removing them would disrupt patient access.

The uncertainty creates planning problems for patients. Starting compounded semaglutide in May 2026 means you might have 4-6 months of access, or you might have 18+ months. No one knows.

The conservative approach: if you start compounded semaglutide, have a transition plan. Know what brand-name semaglutide costs with your insurance. Know whether your provider can switch you to tirzepatide (Mounjaro, Zepbound) if semaglutide becomes unavailable. Don't assume compounded access is permanent.

Quality standards: USP 797 and how compounding pharmacies are regulated

Compounding pharmacies operate under United States Pharmacopeia (USP) Chapter 797, which sets standards for sterile compounding. The standards cover cleanroom design, air quality, personnel training, sterility testing, and beyond-use dating.

Key USP 797 requirements for compounded injectables:

• ISO Class 5 cleanroom environment. Air filtration to remove 99.99% of particles 0.3 microns or larger.
• Sterility testing. Every batch must be tested for bacterial and fungal contamination before release.
• Endotoxin testing. Required for high-risk compounding (though many pharmacies skip this for medium-risk products like semaglutide).
• Beyond-use dating. The pharmacy must establish how long the compounded product remains sterile and potent. For semaglutide, this is typically 28-42 days refrigerated.
• Personnel competency. Pharmacists and technicians must pass annual media-fill tests (sterile technique validation).

USP 797 is enforceable by state pharmacy boards, not the FDA. Compliance varies. Some states (California, Texas, Florida) conduct regular inspections. Others inspect only after complaints.

The FDA has limited authority over compounding pharmacies unless they cross into "manufacturing" territory (producing large batches for distribution to multiple states without individual prescriptions). When that happens, the pharmacy falls under Section 503B instead of 503A, which triggers FDA oversight.

Most telehealth platforms work with 503A pharmacies (patient-specific compounding) to avoid FDA jurisdiction. A few work with 503B outsourcing facilities, which have tighter federal oversight but can produce larger batches more efficiently.

The quality question patients should ask: does the pharmacy conduct third-party potency testing? USP 797 requires sterility testing but not potency testing. A vial can be sterile but contain 0.7 mg of semaglutide when the label says 1 mg. Third-party labs (like Analytical Research Laboratories or Empower Pharmacy's in-house testing) verify that the dose matches the label.

FormBlends works exclusively with pharmacies that conduct batch potency testing and publish certificates of analysis. Not all platforms do.

Who can prescribe compounded semaglutide and who qualifies

Any licensed prescriber (MD, DO, NP, PA) can prescribe compounded semaglutide. The prescription must be written for an individual patient, not as a standing order.

Patient eligibility criteria vary by provider and platform, but the standard framework follows the FDA's approved indications for Wegovy:

Weight-loss indication:

• BMI ≥30, or
• BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

Diabetes indication (off-label for compounded versions):

• Type 2 diabetes with inadequate control on metformin or other oral agents

Exclusions (contraindications):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy or planned pregnancy within 2 months
• History of pancreatitis (relative contraindication, provider discretion)
• Severe gastroparesis
• Active gallbladder disease

Some providers apply stricter criteria. Some require documented diet and exercise attempts before prescribing. Others prescribe based on BMI alone.

Telehealth platforms have made access significantly easier. A patient in rural Montana with no local obesity medicine specialist can complete an online intake, have a video visit with a provider licensed in Montana, and receive a prescription shipped to their door within 5-7 days.

The ease of access has generated criticism. The American Board of Obesity Medicine published a position statement in 2025 expressing concern about "inadequate evaluation and monitoring" in some telehealth GLP-1 programs. The concern is valid. A 10-minute video visit is not a substitute for comprehensive metabolic evaluation.

The middle ground: telehealth expands access, but patients should expect a real clinical evaluation (history, medication review, contraindication screening) and ongoing monitoring (monthly check-ins, dose adjustments based on tolerance and response). Platforms that prescribe after a 5-question form without provider interaction are operating outside the standard of care.

The FormBlends Three-Source Verification Model

One of the challenges in the compounded medication space is transparency about what you're actually receiving. Patients don't tour the compounding pharmacy. They don't see the cleanroom. They take it on faith that the vial contains what the label says.

FormBlends developed a three-source verification model to address this. Every batch of compounded semaglutide we dispense is verified through three independent checkpoints:

Source 1: API supplier certification. We require a certificate of analysis (CoA) from the API manufacturer showing purity ≥98% and endotoxin levels below USP limits. The CoA must be from an FDA-registered supplier.

Source 2: Pharmacy sterility testing. The compounding pharmacy tests every batch for sterility per USP 797. We require documentation that the batch passed before it ships.

Source 3: Third-party potency testing. We send random samples from each batch to an independent lab (Analytical Research Laboratories, based in Oklahoma) for potency verification. The lab confirms the concentration is within ±5% of label claim.

This is more rigorous than USP 797 requires. Most compounding pharmacies do Source 1 and Source 2. Source 3 is optional, and many skip it because it adds $150-$300 per batch in testing costs.

The model isn't perfect. We test random samples, not every vial. A bad vial could slip through. But the three-checkpoint system catches formulation errors, contamination, and degradation that single-source verification misses.

We publish aggregated testing data quarterly on our transparency page. As of Q1 2026, 98.7% of tested batches were within ±5% of label claim. The 1.3% that failed were quarantined and not dispensed.

This level of transparency is rare in the compounding space. It's also the standard we think should be universal.

When compounded semaglutide makes sense and when it doesn't

Compounded semaglutide is a good fit for patients who:

• Have no insurance coverage for Wegovy or Ozempic, or have coverage with a $500+ monthly copay
• Are comfortable with manual injections and reconstitution
• Understand the temporary nature of compounded availability
• Want the same medication at a fraction of the cost and are willing to accept slightly higher variance in dosing precision

Compounded semaglutide is a poor fit for patients who:

• Have insurance that covers brand-name semaglutide with a reasonable copay ($50-$150/month). Use your insurance. The brand-name product has better stability data and tighter quality control.
• Are uncomfortable with needles or lack the dexterity for manual injection. The auto-injector pen is significantly easier.
• Want guaranteed long-term access. Compounded semaglutide could disappear in 6 months.
• Have a history of medication non-adherence. The added complexity of reconstitution and manual dosing increases the risk of errors and missed doses.

The decision often comes down to cost tolerance. If you can afford $1,200/month for Wegovy, the brand-name product is objectively better (easier, more stable, permanent availability). If you can't, compounded semaglutide at $200/month is a reasonable alternative with acceptable trade-offs.

The middle case is trickier: patients with insurance coverage but high copays ($400-$600/month). Some choose to pay the copay for the convenience and quality assurance. Others switch to compounded versions and pocket the savings. There's no wrong answer. It depends on your financial situation and risk tolerance.

FAQ

What is compounded semaglutide? Compounded semaglutide is the same active ingredient as Ozempic and Wegovy, prepared by a licensed compounding pharmacy instead of a pharmaceutical manufacturer. It's legally available during FDA-declared drug shortages under Section 503A exemptions. Patients receive a vial of powder or solution and inject it weekly using a manual syringe.

Is compounded semaglutide the same as Ozempic? The active ingredient (semaglutide) is identical. The differences are in formulation, delivery method, and regulatory status. Ozempic is FDA-approved and comes in a pre-filled pen. Compounded semaglutide is not FDA-approved and requires manual injection from a vial. The molecule and mechanism are the same.

Is compounded semaglutide FDA-approved? No. Compounded medications are exempt from FDA approval under Section 503A when prepared by a licensed pharmacy for an individual patient. They have not undergone the same safety and efficacy trials as FDA-approved drugs.

How much does compounded semaglutide cost? Typical cost is $150-$350 per month out-of-pocket, depending on the pharmacy and telehealth platform. Some platforms offer pricing as low as $99/month with subscription fees. Brand-name semaglutide costs $900-$1,350/month without insurance.

Does insurance cover compounded semaglutide? Rarely. Most insurance plans do not cover compounded medications because they are not FDA-approved. Some self-funded employer plans have started covering compounded GLP-1s as a cost-saving measure, but this is uncommon as of 2026.

How do I inject compounded semaglutide? You reconstitute the lyophilized powder with bacteriostatic water (if not pre-mixed), draw the prescribed dose into an insulin syringe, and inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites weekly. Detailed instructions and video tutorials are provided by your pharmacy or telehealth platform.

Is compounded semaglutide safe? When prepared by a licensed, USP 797-compliant compounding pharmacy, compounded semaglutide has a comparable safety profile to brand-name products. The risks are the same (nausea, vomiting, potential pancreatitis, gallbladder issues). The additional risk is dosing variance if the pharmacy has poor quality control. Choose pharmacies that conduct third-party potency testing.

What happens if semaglutide comes off the FDA shortage list? Compounding pharmacies must stop producing compounded semaglutide within 60 days of removal from the shortage list. Patients would need to transition to brand-name Ozempic or Wegovy, switch to a different GLP-1 medication, or discontinue treatment. The FDA has not announced a timeline for removing semaglutide from the shortage list as of April 2026.

Can I switch from Ozempic to compounded semaglutide? Yes. The dosing is equivalent. If you're taking Ozempic 1 mg weekly, you would continue 1 mg weekly with the compounded version. Your provider will write a new prescription specifying the dose and concentration. Most patients switch without interruption or side effects.

Can I switch from compounded semaglutide back to Wegovy? Yes. The transition is seamless because the active ingredient and dosing are the same. If you're taking compounded semaglutide 2.4 mg weekly, you would switch to Wegovy 2.4 mg weekly. The main adjustment is switching from a manual syringe to the auto-injector pen.

How long does compounded semaglutide last after reconstitution? Most formulations are stable for 28 days refrigerated after reconstitution. Some pharmacies claim 42-day stability based on internal testing. Always follow the beyond-use date on your vial label. Discard any unused medication after the expiration date.

Where can I get compounded semaglutide? Through a telehealth platform (like FormBlends) or a local compounding pharmacy with a prescription from a licensed provider. Telehealth platforms handle the entire process: consultation, prescription, pharmacy fulfillment, and shipping. Local compounding pharmacies require you to obtain a prescription separately and pick up the medication in person.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound medications for individual patients based on specific prescriptions. They are regulated by state pharmacy boards. 503B outsourcing facilities produce larger batches for distribution and are regulated by the FDA. Both can legally compound semaglutide during the shortage, but 503B facilities have stricter federal oversight.

Can compounded semaglutide be used for diabetes? Yes, though it's off-label. Ozempic is FDA-approved for type 2 diabetes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. Many providers prescribe compounded semaglutide for diabetes management, typically at doses of 0.5 mg to 1 mg weekly.

Do I need a prescription for compounded semaglutide? Yes. Compounded semaglutide is a prescription medication. You need an evaluation by a licensed provider (MD, DO, NP, or PA) who will assess your eligibility and write a prescription to a compounding pharmacy.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. FDA Drug Shortages Database. Semaglutide Injection. Accessed April 2026.
5. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
6. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 1997.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
11. American Board of Obesity Medicine. Position Statement on Telehealth GLP-1 Prescribing. 2025.
12. Novo Nordisk. Q4 2025 Earnings Call Transcript. February 2026.
13. Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.